Skip to main content
GALECTIN THERAPEUTICS INC logo

GALECTIN THERAPEUTICS INC — Investor Relations & Filings

Ticker · GALT ISIN · US3632252025 LEI · 5299004HFYSAZM2ALW85 US Manufacturing
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2014-05-13 Interim / Quarterly Rep…
Country US United States of America
Listing US GALT

About GALECTIN THERAPEUTICS INC

https://galectintherapeutics.com/

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases, chronic liver disease, and cancer. The company's therapeutic approach centers on inhibiting the galectin-3 protein, which is implicated in various inflammatory, fibrotic, and malignant conditions. Its lead drug candidate, belapectin (GR-MD-02), is a proprietary carbohydrate-based drug designed to bind to and inhibit galectin-3. The primary development program for belapectin is focused on treating non-alcoholic steatohepatitis (MASH) with cirrhosis, a serious liver disease with no currently approved therapies.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2014
2014-05-13 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text indicates it is furnishing a press release related to a corporate update following the company's 2014 Annual Meeting of Shareholders. The document is short (3085 characters) and primarily serves to provide notice of the press release and the upcoming corporate update audio access. It does not contain detailed financial statements, management discussion, or full report content. It also explicitly states the information is being furnished and not filed, and it is not incorporated by reference. This aligns with a Regulatory Filing (RNS) as a general regulatory announcement rather than a full report like an Annual Report (10-K) or Interim Report (IR).
2014-05-08 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated April 23, 2014, by Galectin Therapeutics Inc. It includes a Regulation FD Disclosure referencing an attached press release (Exhibit 99.1). The document explicitly states that the press release is being furnished and not filed, and no financial statements or substantive financial data are included. The length is 2894 characters, which is relatively short and mainly serves as an announcement of the press release rather than containing detailed financial or operational data. Therefore, this document is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and often include such announcements and disclosures.
2014-04-23 English
PRIMARY DOCUMENT
Director's Dealing
2014-04-18 English
PRIMARY DOCUMENT
Director's Dealing
2014-04-14 English
Regulatory Filings 2014
Regulatory Filings
2014-04-01 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.